Medication Safety in Cirrhosis: Atarax, Losartan, and Albuterol
Losartan should be avoided in patients with cirrhosis and ascites, while hydroxyzine (Atarax) carries significant risk of precipitating hepatic encephalopathy and should generally be avoided; albuterol appears safe but requires monitoring for electrolyte disturbances.
Losartan (Angiotensin II Receptor Blocker)
Clear Contraindication in Ascites
The 2018 EASL guidelines explicitly state that angiotensin II receptor antagonists should not generally be used in patients with ascites because of increased risk of renal impairment 1. This is a strong recommendation based on the pathophysiology of cirrhosis with ascites, where maintenance of adequate arterial pressure depends on activation of endogenous vasoconstrictor systems. Blocking these systems with losartan can induce:
- Arterial hypotension
- Renal function impairment
- Worsening sodium retention
Pharmacokinetic Concerns
The FDA labeling confirms that in patients with mild to moderate alcoholic cirrhosis, losartan plasma concentrations are 5-times higher than in healthy volunteers, with oral bioavailability approximately doubled and total plasma clearance reduced by 50% 2. This dramatically increases exposure and risk of adverse effects.
If the patient does NOT have ascites: The evidence is more nuanced. Research suggests low-dose losartan may actually improve sodium handling in preascitic cirrhosis 3 and potentially reduce portal pressure 4, 5, 6. However, given the guideline recommendation and risk of precipitating decompensation, losartan should still be avoided or used only with extreme caution and close monitoring in any cirrhotic patient.
Hydroxyzine (Atarax)
Significant Hepatic Encephalopathy Risk
While one small randomized trial showed hydroxyzine 25 mg improved sleep in patients with minimal hepatic encephalopathy 7, one patient developed acute encephalopathy requiring drug cessation. The authors themselves concluded that "the risk of precipitating overt HE warrants some caution when prescribing this drug" 7.
Hydroxyzine should be avoided in cirrhotic patients due to:
- Risk of precipitating or worsening hepatic encephalopathy
- Sedative effects that can mask or worsen cognitive dysfunction
- Lack of safety data in decompensated cirrhosis
If sedation or antihistamine therapy is absolutely necessary, consider alternatives with less CNS penetration or hepatic metabolism.
Albuterol
Appears Safe with Monitoring
Albuterol is not mentioned in the EASL cirrhosis guidelines as a contraindicated medication 1. The guidelines specifically list NSAIDs, angiotensin-converting enzyme inhibitors, angiotensin II antagonists, α1-adrenergic blockers, and aminoglycosides as drugs to avoid.
Albuterol can be used in cirrhotic patients with appropriate monitoring for:
- Electrolyte disturbances (hypokalemia, hypomagnesemia) - particularly important as cirrhotic patients often have baseline electrolyte abnormalities
- Tachycardia and cardiovascular effects - especially relevant if the patient has cirrhotic cardiomyopathy
- Fluid retention - beta-agonists can theoretically worsen fluid status
Clinical Algorithm
For a patient with cirrhosis:
Determine presence of ascites:
Evaluate hydroxyzine:
- Discontinue in all cirrhotic patients due to encephalopathy risk 7
- If antihistamine needed, consider non-sedating alternatives
Assess albuterol:
- Continue if needed for respiratory indication
- Monitor electrolytes, particularly potassium
- Watch for signs of fluid retention or cardiovascular instability
Common Pitfalls to Avoid
- Do not assume that because a patient tolerates losartan before developing ascites, it remains safe afterward
- Do not overlook the dramatically increased losartan exposure in cirrhosis (5-fold increase) 2
- Do not prescribe sedating antihistamines like hydroxyzine without considering encephalopathy risk
- Do not forget that even "safe" medications like albuterol require closer monitoring in cirrhosis due to baseline metabolic derangements